Sabby Management’s Evoke Pharma EVOK Stock Holding History

Sabby Management’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-8	Closed	-$289K	–	172
2020 Q4	$289K	Sell	8 -3	-27%	-$1.55K	0.06%	76
2020 Q3	$712K	Buy	+11	New	+$7.02K	0.11%	73

Other funds holding EVOK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cornerstone Capital Palo Alto, California $1B AUM 21.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Wambolt & Associates Littleton, Colorado $297M AUM 17.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management's EVOK Position: Q1 2022 in Review

Sabby Management sold out of Evoke Pharma (EVOK) in Q1 2022, closing a stake of 611 shares — an estimated $48K sold.

Sabby Management first reported a position in EVOK in Q3 2016 and held it in 6 quarters. The position peaked at $168K in Q4 2020. 20 funds tracked by Wall St. Rank hold EVOK as of Q1 2022.

Sabby Management reported no remaining Evoke Pharma position as of Q1 2022 after selling out during the quarter.
Sabby Management sold 611 Evoke Pharma shares in Q1 2022, an estimated $48K.
Sabby Management first reported a position in Evoke Pharma in Q3 2016 and held it in 6 quarters.
Sabby Management's Evoke Pharma position peaked at $168K in Q4 2020.
20 funds tracked by Wall St. Rank held Evoke Pharma as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.